References
- Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet. 1999;354: 1932–9.
- Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Eng J Med. 2000;343:1594–602.
- St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 2004; 50:3432–43.
- Ishikawa H. Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999;6:575–97.
- Koyama H, Tsuji M. Genetic and biochemical studies on the activation and cytotoxic mechanism of bredinin, a potent inhibitor of purine biosynthesis in mammalian cells. Biochem Pharmacol. 1983;32:3547–53.
- Tanaka E, Inoue E, Kawaguchi Y, et al. Acceptability and use-fulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol. 2006;16:214–9.
- Kuroda T, Hirose S, Tanabe N, et al. Mizoribine therapy for patients with lupus nephritis: the association between peak miz-oribine concentration and clinical efficacy. Mod Rheumatol. 2007;17:206–12.
- Shida J, Shuto T, Tokito T, et al. Clinical investigation of efficacy by administration of mizoribine once a day for rheumatoid arthritis (in Japanese). Kyushu Riumachi. 2006;26:9–14.
- Tokuda M, Dobashi H, Hiraishi M, et al. Effect of mizoribine pulse therapy on the disease activity of rheumatoid arithritis refractory to the treatment with methotrexate (in Japanese). Rheumatology. 1998;20:519–26.
- Kohriyama K, Hiramatsu Y, Aoyama T, et al. Efficacy of com-bination pulse therapy with methotrexate and mizoribine for patients with rheumatoid arthritis showing escape phenomenon to low-dose methotrexate therapy (in Japanese). Rinsyo Riumachi. 2003;15 :227–34.
- Murai T, Arai K, Fujisawa J, et al. Evaluation of combination pulse therapy with methotrexate and mizoribine for patients with methotrexate-resistant rheumatoid arthritis (in Japanese). Jpn J Joint Dis (in press).
- Nishimura K, Itoh K, Kuga Y, et al. Prevention of joint destruction in rheumatoid arthritis patients receiving combination methotrexate and mizoribine therapy: a two-year, multicenter open-comparison study to methotrexate monotherapy. Prog Med. 2006;26:2163–72.
- Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifica-tion of rheumatoid arthritis. Arthritis Rheum. 1988;31:3315–24.
- Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clin-ical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). Mod Rheumatol. 2007;17(2):178.
- Gerrit JW, Marijin V, Willem L, et al. Development of antiinf-liximab antibodies and relationship to clinical response in patients with rheumatoid arithritis. Arthritis Rheum. 2006;54:711–5.
- van der Bijl AE, Breedveld FC, Antoni CE, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relation-ship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol. 2008;27:1021–8.
- St. Clair EW, Carrie LW, Adedigbo A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451–9.
- Elisabeth H, Mikkel 0, Jan P, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from inflix-imab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis. 2007;66:1184–9.
- Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor a blockers can make sense. Ann Rheum Dis. 2003;62:1195–8.
- Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice versa in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2005;23:795–800.